Literature DB >> 26293122

Etiopathogenesis of Basedow's disease. Trends and current aspects.

P Leporati, G Groppelli, F Zerbini, M Rotondi, L Chiovato1.   

Abstract

Basedow's disease (BD) owes its name to the German physician Karl Adolph von Basedow, who described in 1840 the clinical picture of exophthalmic toxic goitre. More than one century after the seminal paper of Karl von Basedow, the ultimate cause of BD remains to be fully elucidated. In the last years, evidence was accumulated indicating that BD is a polygenic and multifactorial disease that develops as a result of a complex interplay between genetic susceptibility and environmental and endogenous factors, which leads to the loss of immune tolerance to thyroid antigens and in particular to the TSH receptor. Our aim is to review the current knowledge on the pathogenesis of BD. To this purpose, we will firstly focus our attention on the role of genetic factors (the HLA complex, the genes encoding for thyroglobulin, the TSH receptor, CD40, CTLA-4 and PTPN22), and of environmental factors (iodine, infections, psychological stress, gender, smoking, thyroid damage, vitamin D, selenium, immune modulating agents) as possible causes of BD. Taking advantage of the experimental animal models of BD, we will then focus on the immunological mechanisms leading to the loss of tolerance in BD. The pathogenic role played by the chemokine system will be also reviewed.

Entities:  

Keywords:  Basedow; Graves; autoimmunity; chemokines; thyroid

Mesh:

Substances:

Year:  2015        PMID: 26293122     DOI: 10.3413/Nukmed-0739-15-04

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  7 in total

1.  Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial.

Authors:  M Leo; L Bartalena; G Rotondo Dottore; E Piantanida; P Premoli; I Ionni; M Di Cera; E Masiello; L Sassi; M L Tanda; F Latrofa; P Vitti; C Marcocci; M Marinò
Journal:  J Endocrinol Invest       Date:  2016-10-12       Impact factor: 4.256

2.  Oxidative Stress in Graves Disease and Graves Orbitopathy.

Authors:  Giulia Lanzolla; Claudio Marcocci; Michele Marinò
Journal:  Eur Thyroid J       Date:  2020-11-20

3.  Focus on radioiodine-131 biokinetics: the influence of methylprednisolone on intratherapeutic effective half-life of 131I during radioiodine therapy of Graves' disease.

Authors:  C Happel; W T Kranert; D Gröner; J Baumgarten; J Halstenberg; B Bockisch; A Sabet; F Grünwald
Journal:  Endocrine       Date:  2021-01-13       Impact factor: 3.633

Review 4.  Is Graves' disease a primary immunodeficiency? New immunological perspectives on an endocrine disease.

Authors:  Tristan Struja; Alexander Kutz; Stefan Fischli; Christian Meier; Beat Mueller; Mike Recher; Philipp Schuetz
Journal:  BMC Med       Date:  2017-09-25       Impact factor: 8.775

Review 5.  Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.

Authors:  Mario Rotondi; Martina Molteni; Paola Leporati; Valentina Capelli; Michele Marinò; Luca Chiovato
Journal:  Front Endocrinol (Lausanne)       Date:  2017-09-28       Impact factor: 5.555

Review 6.  Selenium in the Treatment of Graves' Hyperthyroidism and Eye Disease.

Authors:  Giulia Lanzolla; Michele Marinò; Claudio Marcocci
Journal:  Front Endocrinol (Lausanne)       Date:  2021-01-26       Impact factor: 5.555

Review 7.  Antioxidant Therapy in Graves' Orbitopathy.

Authors:  Giulia Lanzolla; Claudio Marcocci; Michele Marinò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-14       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.